The risks of biological and immunosuppressant therapies in pregnant patients with rheumatic diseases

被引：0
|
作者：
Cervera, R [1 ]
机构：
[1] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [31] Risks of serious and opportunistic infections in patients with immune-mediated diseases while on biological modifier therapies
    Mak, Joyce Wing Yan
    Lam, Ray Hong Man
    Yip, Terry Cheuk Fung
    Ho, Jacky Chiu Leung
    Lam, Tsz On
    Tam, Lai Shan
    Wong, Grace Lai Hung
    Ng, Siew Chien
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 45 - 45
  • [32] Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
    Sanchez-Piedra, Carlos
    Diaz-Torne, Cesar
    Manero, Javier
    Pego-Reigosa, Jose M.
    Rua-Figueroa, Inigo
    Gonzalez-Gay, Miguel A.
    Gomez-Reino, Juan
    Alvaro-Gracia, Jose M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 988 - 990
  • [33] Novel therapies in pediatric rheumatic diseases
    Chira, P
    Sandborg, CI
    CURRENT OPINION IN PEDIATRICS, 2003, 15 (06) : 579 - 585
  • [34] Cellular therapies in rheumatic and musculoskeletal diseases
    Franco-Fuquen, Pedro
    Figueroa-Aguirre, Juana
    Martinez, David A.
    Moreno-Cortes, Eider F.
    Garcia-Robledo, Juan E.
    Vargas-Cely, Fabio
    Castro-Martinez, Daniela A.
    Almaini, Mustafa
    Castro, Januario E.
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2025, 10
  • [35] Pharmacogenomic approaches to therapies in rheumatic diseases
    Ranganathan, P
    Eisen, S
    DRUG DEVELOPMENT RESEARCH, 2004, 62 (03) : 161 - 171
  • [36] Locus of control and the use of alternative therapies (AT) in patients with rheumatic diseases.
    RamosRemus, C
    SuarezAlmazor, ME
    Dyke, L
    Russell, AS
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1116 - 1116
  • [37] Biological therapy in rheumatic diseases
    Mas, A. Juan
    MEDICINA BALEAR, 2008, 23 (03): : 11 - 16
  • [38] PREVALENCE OF OCCULT HEPATITIS B CARRIER STATUS AND ITS ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATIC DISEASES UNDERGOING BIOLOGICAL THERAPIES
    Mok, C. C.
    Ho, L. Y.
    Chan, K. L.
    Tse, S. M.
    To, C. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 317 - 317
  • [39] SKIN LESIONS INDUCED BY BIOLOGICAL THERAPIES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: ARE THERE ANY DIFFERENCES BETWEEN RHEUMATOID ARTHRITIS AND SPONDYLOARTHROPATHIES?
    Clavaguera, M. T.
    Sanchez-Perez, I.
    Sanchez-Dossantos, M. J.
    Valls-Garcia, R.
    Juanola, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 947 - 948
  • [40] Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
    Castro Perez, Patricia
    Onteniente Gonzalez, Alberto
    Aragon Diez, Angel
    Gallegos Cid, Angel
    Garcia-Arroba Munoz, Jesus
    Rodriguez Heredia, Jose Manuel
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345